Neutrolis Appoints Former Pfizer Chief Scientific Officer Dr. Mikael Dolsten As Executive Director To Its Board To Advance Fast-Acting, Non-Immunosuppressive NET-Targeting Therapies

Neutrolis, a clinical-stage biotechnology company developing a new class of fast-acting, non-immunosuppressive therapies that directly target Neutrophil Extracellular Traps (NETs), announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of Directors as Executive Director. The company’s platform is designed to change the treatment landscape for inflammatory and autoimmune disorders by removing the harmful autoantigens that fuel disease activity.

Dr. Dolsten, who most recently served as Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer Inc., shared that he is impressed by Neutrolis’ science and its potential to reshape therapies for systemic autoimmune diseases. He noted that the company’s approach to clearing pathogenic autoantigens at their source could mark a major shift in how autoimmune conditions are treated. Dr. Dolsten added that important proof-of-concept data expected later this year could significantly influence the company’s trajectory, and he looks forward to working closely with the Board and leadership team during this pivotal period.

During his more than 16 years at Pfizer, Dr. Dolsten oversaw global R&D and contributed to more than 35 regulatory approvals for the company. Throughout his broader career, he has supported around 50 approvals across multiple therapeutic modalities, including small molecules, biologics, gene-based therapies, and vaccines. His experience also includes involvement in corporate transactions totaling over $100 billion in value. 

As a physician scientist and senior biopharmaceutical leader, he has held key positions at Pfizer, Wyeth, Boehringer Ingelheim, AstraZeneca, and Pharmacia. In parallel with his industry work, he serves as an Adjunct and Visiting Professor in immunology and pharmacology at Lund University, has authored more than 160 scientific papers, and is a member of the Royal Swedish Academy of Engineering Sciences.

Gerald Chan, Chairman of Neutrolis and co-founder of Morningside, expressed enthusiasm about Dr. Dolsten’s appointment. He highlighted Dr. Dolsten’s proven record in scientific leadership, strategic decision-making, and global R&D management. Chan emphasized that Dr. Dolsten has repeatedly transformed cutting-edge science into approved medicines and that his insight will be particularly valuable as Neutrolis progresses its therapeutic platform and clinical pipeline. 

With Phase 1b studies in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) planned for mid-2026, the company expects his guidance on clinical strategy, resource allocation, and partnership development to play a crucial role in its advancement. With this appointment, Neutrolis strengthens its leadership team at a time when it is moving toward important clinical milestones and expanding the potential of its NET-targeting therapeutic approach.